Background: While anti-β2 glycoprotein 1 (anti-β2GP1) antibody positivity is included in the diagnostic criteria for antiphospholipid syndrome (APS), the association between anti-β2GP1 and the obstetrical complications of APS has been inconsistently reported and remains unclear.
Objective: We completed a case-control study nested within the Canadian Ottawa and Kingston (OaK) Birth Cohort to evaluate the association between anti-β2GP1 antibody positivity and placenta-mediated pregnancy complications.
Study Design: Five hundred cases were randomly selected among pregnant women who experienced any of the following independently adjudicated placenta-mediated pregnancy complications: preeclampsia, placental abruption, late pregnancy loss (≥ 12 weeks' gestation), and birth of a small-for-gestational age (SGA) infant < 10th percentile. Five hundred pregnant women without any placenta-mediated pregnancy complications were selected as controls. Stored blood samples were analyzed for the presence of anti-β2GP1 antibodies by enzyme-linked immunosorbent assay.
Results: Anti-β2GP1 immunoglobulin G (IgG) and/or immunoglobulin M (IgM) antibodies in titers ≥ 20 G/M units (> 99th percentile) were present in 24 of 497 (4.8%) of controls and 33 of 503 (6.6%) of cases. There was no significant difference between cases and controls for the composite outcome of any placenta-mediated pregnancy complications (odds ratio, 1.38, 95% confidence interval [CI], 0.8-2.37, = 0.25).
Conclusion: Our results call into question the association between anti-β2GP1 antibodies and placenta-mediated pregnancy complications, with further research needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0038-1641168 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of combining aspirin with hydroxychloroquine in pregnancies at high risk for pre-eclampsia: a prospective, multicentre, open-label, single-arm clinical trial, investigator-initiated study (HUGS study).
BMJ Open
December 2024
Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Korea (the Republic of).
Introduction: The use of hydroxychloroquine (HCQ) during pregnancies complicated by systemic lupus erythematosus or refractory antiphospholipid antibody syndrome has demonstrated a significant ability to prevent pre-eclampsia (PE). As such, the potential for the administration of HCQ to prevent PE in other high-risk pregnancies is an important clinical research agenda among maternal and fetal medicine specialists. Mechanistically, the anti-inflammatory and immunomodulatory effects of HCQ can offer vascular protection and inhibit the placental dysfunction-associated thrombotic changes underlying the pathophysiology of PE, fetal growth restriction (FGR) and fetal death in utero (FDIU).
View Article and Find Full Text PDFFirst-Trimester PlGF and PAPP-A and the Risk of Placenta-Mediated Complications: PREDICTION Prospective Study.
J Obstet Gynaecol Can
December 2024
Reproduction, Mother and Child Health Unit, CHU De Québec-Université Laval Research Center, Université Laval, Québec City, Québec, Canada; Department of Obstetrics and Gynecology, Faculty of Medicine, Université Laval, Québec City, Québec, Canada. Electronic address:
Objectives: This study aimed to estimate the association between low first-trimester maternal serum PlGF (placental growth factor) and PAPP-A (pregnancy-associated plasma protein A) and the risk of placenta-mediated complications.
Methods: We performed a secondary analysis of the PREDICTION study, including nulliparous participants recruited at 11 to 14 weeks of pregnancy. First-trimester PlGF and PAPP-A levels were reported in multiples of the median (MoM) adjusted for maternal characteristics and gestational age.
Development and validation of the placenta-QUS model for the detection of placenta-mediated diseases using quantitative ultrasound measurements: An Ex Vivo proof-of-concept study.
Placenta
December 2024
Department of Electrical and Computer Engineering, University of British Columbia, Vancouver, British Columbia, Canada.
Article Synopsis
- The study focuses on developing a diagnostic model using Quantitative Ultrasound (QUS) to predict pre-eclampsia (PE) and small-for-gestational-age (SGA) outcomes in pregnancies.
- Researchers collected placenta samples and ultrasound data from women who had cesarean deliveries, measuring key parameters like attenuation and backscatter to create a logistic regression model.
- The resulting model showed strong predictive ability, with an Area Under the Curve (AUROC) of 0.89, indicating its effectiveness, and future research aims to validate the model with in-utero QUS data.
Expression Levels of PF4, ALOX12, ITGA2B, F131A in Pregnant COVID-19 Survivors.
Biochem Genet
November 2024
Medical Molecular Genetics Department, Human Genetics and Genome Research Institute, National Research Centre, Cairo, Egypt.
COVID-19 is viral illness caused by SARS-CoV-2. The immediate complications of COVID-19 are well defined and associated with increased mortality. A global effort is required to determine its effects on implantation, fetal growth and labor.
View Article and Find Full Text PDFPlacenta-Mediated Conditions: Past, Present, and Future Perspectives.
J Clin Med
August 2024
Laboratory of Blood and Vascular Biology, Rockefeller University, New York, NY 10065, USA.
Pregnancy is a highly regulated biological condition in which a successful outcome is heavily dependent on maintaining a delicate balance through maternal-fetal dialog at various levels [...
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!